Lilly’s Retevmo meets primary endpoint in Phase 3 LIBRETTO-531 study
The trial compared Retevmo against physician's choice of the MKIs vandetanib or cabozantinib as an initial treatment and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Aug 23
The trial compared Retevmo against physician's choice of the MKIs vandetanib or cabozantinib as an initial treatment and…
23 Aug 23
The approval was based on the findings from the Phase 3 CheckMate -76K trial in which Opdivo lowered…
23 Aug 23
The American biotechnology company is now submitting applications for its XBB.1.5 Covid vaccine candidate to regulatory agencies all…
23 Aug 23
Under the terms of the cooperation agreement, Sanyou will leverage its globally renowned core technology platform to undertake…
23 Aug 23
Groundbreaking discovery to be used as basis for Verismo's SynKir-310 to target blood cancer
23 Aug 23
Genetic Signatures, a leading innovator in molecular diagnostics, is pleased to announce a new channel partner in the…
23 Aug 23
Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials…
22 Aug 23
Abrysvo, a bivalent RSV prefusion F (RSVpreF) vaccine that contains two preF proteins to optimise the protection against…
22 Aug 23
According to Gilead Sciences, the screening and recruitment of new participants under the US Expanded Access Programme and…
22 Aug 23
The late-stage trial evaluated cabozantinib combination against a second hormonal therapy in mCRPC patients which showed a statistically…